Application of Nanoparticle Platforms to Antiviral Therapy and Vaccines
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Human Virology and Viral Diseases".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 213
Special Issue Editor
Interests: antibody discovery; antiviral therapy; drug delivery; infectious disease; nanoparticle; rational vaccine design; vaccine delivery; virus-like particle
Special Issue Information
Dear Colleagues,
The delivery of small-molecule drugs and viral antigens using nanoparticle carriers has attracted much attention in recent research on antiviral therapy and vaccines, respectively. With structural features that resemble the size (up to 200 nm) and shape (spherical ball) of real viruses as well as tunable surface chemistry, nanoparticles can circulate through the bloodstream and/or lymphatic system to enter specific organs to interact with viruses and infected cells in diseased tissues or stimulate immune responses to vaccination in secondary lymphoid organs. Such nanoparticles can be derived from polymers, liposomes, inorganic materials, and/or proteins. Nanoparticles can serve as delivery systems for antiviral drugs and viral antigens, which can be displayed multivalently on the particle surface or encapsulated for more efficient intercellular and intracellular interactions in vivo compared to soluble antiviral agents; however, despite encouraging advancements, the application of nanoparticles to the prevention and treatment of viral diseases is still in its infancy.
In this Special Issue, we will focus on the most recent advances in the rational design of nanoparticle platforms for antiviral therapy and vaccines, the investigation of the mechanisms of nanoparticle transport, distribution, and interaction at the intra-organ and cellular levels, and multifunctional nanoparticle approaches that incorporate several antiviral drugs or vaccine antigens and adjuvants. We will also discuss the recent progress in the development of antiviral drugs, antibodies, and vaccines and their paths to commercialization.
Dr. Jiang Zhu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoparticle platform
- rational design
- antiviral drugs
- neutralizing and non-neutralizing antibodies
- vaccines
- infectious diseases
